• Publications
  • Influence
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Results from PSOLAR suggest a higher risk of serious infections with adalimumab and infliximab compared with nonmethotrexate and nonbiologic therapies.
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Extended exposure to 50 mg of etanercept twice weekly resulted in exposure-adjusted rates of adverse events and infections similar to those in patients receiving placebo, and improvements in physician- and patient-reported measures of psoriasis severity were observed for up to 96 weeks of continuous etanerscept therapy.
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
Calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated.
Topical treatment of actinic keratoses with 3·0% diclofenac in 2·5% hyaluronan gel
The development of an effective and well‐tolerated topical treatment for AK is desirable and this work contributes towards that goal.